Publications & Presentations
Andrews, D.W., et al. “Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.” Clinical Cancer Research, April 2021. DOI 10.1158/1078-0432.CCR-20-3805
Zilberberg, J., et al. “Autologous glioblastoma tumor cells treated with an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect mice against GL261 tumor challenge.” Presented at AACR 2021.
Zilberberg, J., et al. “Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses.” Presented at SITC 2021.
Exley, M.A., et al. “Challenges and opportunities for immunotherapeutic intervention against myeloid immunosuppression in glioblastoma.” Journal of Clinical Medicine, Feb. 2022. DOI 10.3390/jcm11041069
Zilberberg, J., et al. “Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges.” Presented at AACR 2022.
Uhl, C., et al. “Machine learning algorithm identifies key serum cytokines associated with evidence of clinical activity in patients treated with personalized immunotherapeutic platform (IGV-001).” Presented at AACR 2022.